Most SaaS founders meet non-dilutive capital at the worst possible moment, right when growth is finally working, the pipeline is full, and the only thing standing between this month and a much bigger one is cash to spend on acquisition. Selling equity to cover that gap is the expensive option. A $3M cheque at a $30M valuation costs you ten points of the company, and you pay for it with the most valuable shares you will ever own: the cheap, early ones.
So you start reading about alternatives, and three names keep coming up: revenue-based financing, venture debt, and, more and more often, financing built directly around customer acquisition cost. They sound interchangeable. They are not. Each one prices risk differently, repays differently, and fits a different shape of business. This guide breaks down how each works, what it really costs once you do the arithmetic, and how to match the instrument to your unit economics instead of to whichever provider emailed you first.
The three non-dilutive paths at a glance
The short version, before the mechanics:
| Factor | Revenue-based financing | Venture debt | CAC-financing |
|---|---|---|---|
| What backs it | A slice of all future revenue | The whole company, plus warrants | The recurring revenue a specific acquisition spend produces |
| How you repay | A fixed percentage of monthly revenue until a cap | Scheduled principal and interest, often after an interest-only period | From the contracted revenue the funded cohort generates |
| Headline cost | A 1.3x to 2.5x cap, or a 5% to 15% flat fee | Roughly 10% to 14% interest, plus warrants | Priced against CAC payback, not a blanket multiple |
| Real dilution | None | Small but real (warrants, 0.1% to 1%) | None |
| Who qualifies | Any predictable recurring revenue | Usually needs institutional VC backing | Needs measurable CAC payback and retention |
| Best-fit stage | Early revenue through Series A | Post Series A, bridging rounds | Series A and B with clean cohort data |
| Biggest risk | Gets expensive if you grow fast | Covenants and fixed payments in a downturn | Mispriced if your retention slips |
Revenue-based financing: flexible until you grow fast
Revenue-based financing (RBF) is the easiest of the three to understand. A provider advances capital, often 1x to 4x your monthly recurring revenue or 20% to 70% of ARR, and you repay by remitting a fixed percentage of revenue each month until you have returned the principal plus a flat fee. Subscription revenue is predictable and simple to verify, so a provider can underwrite an MRR feed in days rather than weeks. There are no board seats, no warrants, and no personal guarantee. For a founder watching the cap table, that is the appeal.
The catch hides in the word "flat." A flat fee sounds cheaper than an interest rate because it never compounds. But a fee is a fixed dollar amount, and the faster you repay it, the higher its true annualised cost. Borrow $1M against a 1.5x cap and you owe $1.5M, a $500k fee. Clear that in 12 months because your revenue is climbing, and the $500k behaves like a 50% to 60% annualised rate on the capital you actually had outstanding. Stretch the same fee over 30 months and it lands closer to 20%. RBF quietly punishes the companies it is marketed to: the ones growing fast enough to repay early.
That makes RBF a strong fit for steady, repeatable spend, things like topping up ad budgets, funding inventory, or smoothing seasonality, where the payback window is short and you are not in a rush to retire the facility. It is a poor fit for a once-in-a-company growth sprint, because the better the sprint works, the more the fee costs you for every dollar of time. For a closer look at one of the providers that built a business on this model, see our profile of Pipe.
Venture debt: a loan that quietly takes equity
Venture debt is a term loan for companies that have already raised institutional equity. The structure is familiar: a fixed interest rate, often an interest-only period of 6 to 12 months, then amortisation over the rest of the term. A $2M facility at 12% over two years costs roughly $240k to $280k in interest plus the principal, noticeably cheaper on paper than an RBF cap.
Two details complicate the "non-dilutive" label that lenders like to attach to it. First, almost every venture debt deal includes warrants, the right to buy stock at today's price later. That is real dilution, usually between 0.1% and 1%, small next to a Series A round but not zero. Second, the loan carries covenants and often a material-adverse-change clause. In a good year these are invisible. In a bad one, a missed quarter or a delayed round, they hand the lender leverage at the exact moment you have none. Fixed payments do not flex with your revenue the way RBF does; they are due whether the month was strong or weak.
Venture debt earns its place as a runway extender. If you have raised a Series A, have a credible path to the next round, and want to hit more milestones before you price it, a debt facility buys you months without resetting your valuation. It is a bridge, not a growth engine, and it works best when you genuinely do not expect to have the covenants tested.
CAC-financing: treating acquisition as a capital expenditure
The third path starts from a different question. RBF asks how much revenue you have. Venture debt asks who backs you and what it can claim. CAC-financing asks what a dollar of acquisition spend turns into, and how reliably.
The logic is simple once you say it out loud. For a SaaS business with strong retention, customer acquisition cost is not really an operating expense. It behaves like a capital expenditure. You spend once to win a customer, and that customer pays you back over months or years of recurring revenue. A factory that produced a 14-month-payback annuity would be financed as an asset. Sales and marketing that produces a 14-month-payback annuity usually is not, mostly out of accounting habit. That gap is the whole idea behind the EBITCAC lens: read acquisition spend as investment in a revenue-producing asset, and you can finance it against the specific future revenue it creates rather than against the entire company.
Because the underwriting is tied to one measurable asset, a cohort with a known payback and a known retention curve, the pricing follows the unit economics instead of a blanket multiple or your investor pedigree. There are no warrants and no equity, the same as RBF, but the capital is matched to the thing it funds. It suits founders who can show clean cohort data: a CAC payback inside roughly 18 months, net revenue retention comfortably above 90%, and channels predictable enough to scale. If your retention is shaky, this path will price that risk straight back to you, which is the honest version of a feature. You can check whether your cohorts fit this kind of financing before you ever talk to anyone.
The decision math: start with CAC payback, not the term sheet
The mistake founders make is comparing offers by headline rate. The better starting point is your own numbers. Two figures decide most of this: how long a customer takes to pay back their acquisition cost, and how much of that revenue survives a year (net retention).
- CAC payback under about 12 months, retention above 90%. Your growth spend is a high-quality asset. CAC-financing or RBF lets you pour fuel on it without touching the cap table. Between the two, prefer the one whose cost structure matches your repayment speed: RBF if you will repay slowly, CAC-financing if you want pricing tied to the cohort itself.
- Institutional VC behind you, a round on the horizon. Venture debt is the cheapest way to buy runway to that round, as long as you are confident you will not be relying on the lender's goodwill if a quarter slips.
- Early, thin data, product-market fit still forming. None of these is a substitute for equity. Debt taken against revenue you cannot yet predict is a fast way to turn a soft quarter into a solvency problem.
Stage matters because it changes what can be underwritten. At Series A you often have enough revenue for RBF but not yet enough cohort history for a clean CAC underwrite. By Series B, with several quarters of retention data behind you, financing the acquisition engine directly becomes both possible and usually the cheapest non-dilutive dollar you can raise.
Stacking capital across Series A and B
These instruments are not mutually exclusive, and the strongest operators rarely pick just one. A common sequence looks like this: raise equity for the genuinely risky, unfinanceable work, things like R&D, the first go-to-market hires, anything without a payback you can model. Layer venture debt on top to extend runway between priced rounds. Then fund the predictable, repeatable growth spend with RBF or CAC-financing, so you are not burning equity dollars on something a lender will happily underwrite at a fraction of the cost.
Done well, the cap table absorbs only the risk that nothing else will price, and the predictable parts of the business are paid for by the revenue they produce. Done badly, equity goes to ad spend and you end up with debt covenants you cannot clear, which means you paid the most for the things that were cheapest to fund. The order is the strategy.
Frequently asked questions
Is revenue-based financing cheaper than venture debt? Often it looks more expensive on the headline cap, and it can be far more expensive in practice if you repay quickly, because the flat fee does not shrink with time. Venture debt's interest is usually lower, but it adds warrants and fixed payments. Compare the two on annualised cost over your realistic repayment timeline, not on the sticker price.
Is venture debt really non-dilutive? Mostly, but not entirely. The warrants attached to most facilities are genuine equity dilution, small (typically well under 1%) but real. The larger cost is structural: covenants and fixed payments that bite hardest in a weak quarter.
What CAC payback do I need to qualify for CAC-financing? There is no universal cutoff, but a payback inside roughly 18 months paired with net revenue retention above 90% is the kind of profile that underwrites cleanly. The tighter and more predictable your cohorts, the better the terms you will see.
Can I combine these? Yes, and many growth-stage companies do. Equity, venture debt, and revenue- or CAC-based financing each cover a different layer of risk. The art is sequencing them so the cap table only pays for the risk that genuinely cannot be financed any other way.
